CIRB Studies

Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website

To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.

Review CIRB
Study Status
Study Number Sort descending Lead Group Study Title CIRB Study Status
9853 ETCTN A Phase 1 Study of AZD1775 in Combination with Belinostat in Relapsed and Refractory Myeloid Malignancies and Selected Untreated Patients with Acute Myeloid Leukemia Adult CIRB - Early Phase Emphasis Available to Open
9855 ETCTN A Phase 2 Study of CDX-011 (glembatumumab vedotin) for Metastatic Uveal Melanoma Adult CIRB - Early Phase Emphasis Completed
9874 ETCTN A Phase I Trial of AT13387 in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (LA-SCCHN) receiving Concurrent Radiation and Cisplatin Adult CIRB - Early Phase Emphasis Completed
9875 ETCTN Phase 2 Study of AT13387 (onalespib) in ALK+ ALCL; MCL; and BCL-6+ DLBCL Adult CIRB - Early Phase Emphasis Completed
9876 ETCTN Phase 1b Study of HSP90 Inhibitor, AT13387 (onalespib) in Combination with Paclitaxel in Patients with Advanced, Triple Negative Breast Cancer. Adult CIRB - Early Phase Emphasis Available to Open
9878 ETCTN A Phase 1/2 Trial of Erlotinib and Onalespib lactate in EGFR-Mutant Non-Small Cell Lung Cancer Adult CIRB - Early Phase Emphasis Completed
9881 ETCTN A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors Adult CIRB - Early Phase Emphasis Available to Open
9892 ETCTN Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination with Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vulvar Cancer Adult CIRB - Early Phase Emphasis Available to Open
9898 ETCTN A Phase I Trial of AZD9291 and Necitumumab in EGFR-Mutant Non-Small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor Adult CIRB - Early Phase Emphasis Available to Open
9899 ETCTN A Phase 1 Trial of the Combination of the Heat Shock Protein-90 (HSP90) inhibitor Onalespib (AT13387) and the Cyclin-Dependent Kinase (CDK) inhibitor AT7519M in patients with Advanced Solid Tumors Adult CIRB - Early Phase Emphasis Completed